Josh Goldstein, MD, PhD Disclosures: Consulting Fee-AstraZeneca|Consulting Fee-CSL Behring (Relationship has ended)|Consulting Fee-Prothya (Relationship has ended)|Grant or research support-Octapharma|Consulting Fee-Pfizer, Inc. (Relationship has ended)|Ownership-Cayuga|Ownership-NControl (Relationship has ended)|Grant or research support-Takeda Pharmaceuticals, Inc. - 08/07/2024 No Bio Available.